The long road to leptin
- PMID: 27906690
- PMCID: PMC5127673
- DOI: 10.1172/JCI91578
The long road to leptin
Abstract
Leptin is an adipose tissue hormone that functions as an afferent signal in a negative feedback loop that maintains homeostatic control of adipose tissue mass. This endocrine system thus serves a critical evolutionary function by protecting individuals from the risks associated with being too thin (starvation) or too obese (predation and temperature dysregulation). Mutations in leptin or its receptor cause massive obesity in mice and humans, and leptin can effectively treat obesity in leptin-deficient patients. Leptin acts on neurons in the hypothalamus and elsewhere to elicit its effects, and mutations that affect the function of this neural circuit cause Mendelian forms of obesity. Leptin levels fall during starvation and elicit adaptive responses in many other physiologic systems, the net effect of which is to reduce energy expenditure. These effects include cessation of menstruation, insulin resistance, alterations of immune function, and neuroendocrine dysfunction, among others. Some or all of these effects are also seen in patients with constitutively low leptin levels, such as occur in lipodystrophy. Leptin is an approved treatment for generalized lipodystrophy, a condition associated with severe metabolic disease, and has also shown potential for the treatment of other types of diabetes. In addition, leptin restores reproductive capacity and increases bone mineral density in patients with hypothalamic amenorrhea, an infertility syndrome in females. Most obese patients have high endogenous levels of leptin, in some instances as a result of mutations in the neural circuit on which leptin acts, though in most cases, the pathogenesis of leptin resistance is not known. Obese patients with leptin resistance show a variable response to exogenous leptin but may respond to a combination of leptin plus amylin. Overall, the identification of leptin has provided a framework for studying the pathogenesis of obesity in the general population, clarified the nature of the biologic response to starvation, and helped to advance our understanding of the neural mechanisms that control feeding.
Conflict of interest statement
Leptin is now an approved drug. While Rockefeller University owns the patent for leptin, the author is named as an inventor on the patent for leptin and, as per University policy, receives a portion of the milestone and royalty payments made to Rockefeller University by Astra Zeneca, the company that owns the license to the patents.
References
-
- Ogburn WF, Thomas D. Are inventions inevitable? A note on social evolution. Polit Sci Q. 1922;37(1):83–98. doi: 10.2307/2142320. - DOI
-
- Merton R. Singletons and multiples in scientific discovery: A chapter in the sociology of science. Proc Am Philosophical Soc. 1961;105(5):470–486.
-
- Gladwell M. Annals of Innovation: In The Air. The New Yorker. May 12, 2008. http://www.newyorker.com/reporting/2008/05/12/080512fa_fact_gladwell Accessed November 14, 2016.
-
- Kreek MJ, et al. Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci. 1983;33(Suppl 1):409–411. - PubMed
-
- Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J Hered. 1950;41(12):317–318. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
